Regeneron Pharmaceuticals and Sanofi announced successful results from the DISCOVER Phase 4 trial for Dupixent® (dupilumab), demonstrating significant efficacy in treating moderate-to-severe atopic dermatitis in 120 adults and adolescents with skin of color. The trial, presented at the 2025 Revolutionizing Atopic Dermatitis Conference, revealed that 76% of participants achieved a 75% or greater improvement in disease severity, with notable symptom relief in itchiness and dry skin.
The study’s demographic included 82% Black participants, emphasizing the need for improved clinical insights in communities of color. Notably, 53% of patients reported meaningful improvements in itch, while 53% experienced reduced post-inflammatory hyperpigmentation. Despite these positives, the trial reported a 42% adverse event rate, raising concerns regarding drug tolerability.
Results indicated that atopic dermatitis is prevalent among communities of color and displayed unique clinical features that may impact diagnosis and treatment. Further exploration into Dupixent’s long-term effects and safety in diverse patient populations will be critical.
